Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 1/20 | 0.58 |
| ▸ | NPY2R | P49146 | 1/20 | 0.58 |
| ▸ | NPY4R | P50391 | 1/20 | 0.58 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.56 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.55 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.54 |
| ▸ | CHRNG | P07510 | 1/20 | 0.54 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.54 |
| ▸ | CHRND | Q07001 | 1/20 | 0.54 |
| ▸ | MME | P08473 | 1/20 | 0.54 |
| ▸ | GNPAT | O15228 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31347785 | 0.97 | ERAP2 (0.60) | NPY1RNPY2RNPY4RERAP2LNPEP | |
| SCHEMBL31474739 | 0.97 | ERAP2 (0.60) | NPY1RNPY2RNPY4RERAP2LNPEP | |
| SCHEMBL30591078 | 0.97 | ERAP2 (0.60) | NPY1RNPY2RNPY4RERAP2LNPEP | |
| SCHEMBL30523241 | 0.97 | ERAP2 (0.60) | NPY1RNPY2RNPY4RERAP2LNPEP | |
| SCHEMBL30712028 | 0.97 | ERAP2 (0.60) | NPY1RNPY2RNPY4RERAP2LNPEP | |
| SCHEMBL29462359 | 0.97 | ERAP2 (0.60) | NPY1RNPY2RNPY4RERAP2LNPEP | |
| SCHEMBL23510636 | 0.96 | LNPEP (0.60) | NPY1RNPY2RNPY4RERAP2LNPEP | |
| SCHEMBL23510635 | 0.96 | LNPEP (0.60) | NPY1RNPY2RNPY4RERAP2LNPEP | |
| SCHEMBL30931517 | 0.94 | LNPEP (0.62) | NPY1RNPY2RNPY4RERAP2LNPEP | |
| SCHEMBL30118045 | 0.94 | LNPEP (0.62) | NPY1RNPY2RNPY4RERAP2LNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11672841-B2 | Methods for treating heart disease in a subject with Friedreich's ataxia by an aromatic-cationic peptide | STEALTH BIOTHERAPEUTICS INC. (US) | 2023-06-13 | — | — | US | disclosed |
| EP-4000690-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF MITOCHONDRIAL MYOPATHIES | Stealth BioTherapeutics Inc. (US) | 2022-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11672841-B2 | Methods for treating heart disease in a subject with Friedreich's ataxia by an aromatic-cationic peptide | HAGH, OAT, NLN | NPY1R 743/4885NPY2R 799/4885NPY4R 886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.